
Quarterly ResultAug 12, 2026, 04:07 PM
Acrivon Therapeutics Advances Pipeline; Q2 Net Loss $18M; Cash to Q4 2027
AI Summary
Acrivon Therapeutics reported a net loss of $18.0 million for the second quarter of 2026, an improvement from $21.0 million in the same period last year. The company ended the quarter with $90.0 million in cash, cash equivalents, and marketable securities, providing a runway into the fourth quarter of 2027. Significant progress was made in its clinical pipeline, with the ACR-368 Phase 2b interim analysis expected in H2 2026 and the ACR-2316 Phase 1/2 trial advancing into its randomized dose expansion phase. Additionally, the CDK11 inhibitor program is moving forward with IND-enabling studies.
Key Highlights
- Net loss for Q2 2026 was $18.0 million, compared to $21.0 million in Q2 2025.
- Cash, cash equivalents, and marketable securities totaled $90.0 million as of June 30, 2026.
- Cash runway is expected to fund operations into the fourth quarter of 2027.
- ACR-368 Phase 2b interim analysis and data are on track for the second half of 2026.
- ACR-2316 Phase 1/2 trial advanced into the randomized dose expansion phase.
- CDK11 inhibitor program is advancing in Investigational New Drug (IND)-enabling studies.
- Research and development expenses decreased to $13.8 million in Q2 2026 from $16.2 million YoY.
- General and administrative expenses decreased to $4.8 million in Q2 2026 from $6.5 million YoY.
Price Impact
More from ACRV